The development and use of the E75 (HER2 369-377) peptide vaccine

被引：40

作者：

Clifton, Guy T. ^{[1
]}

Peoples, George E. ^{[2
]}

Mittendorf, Elizabeth A. ^{[3
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,Unit 1484, Houston, TX 77030 USA

[2] Metis Fdn, Canc Vaccine Dev Program, 600 Navarro St, San Antonio, TX 78205 USA

[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Surg Oncol, 1400 Pressler St,Unit 1434, Houston, TX 77030 USA

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 11期

关键词：

breast cancer; cancer vaccine; E75; nelipepimut-S; peptide; T-CELL RESPONSES; GROUP-STUDY I-01; CLINICAL-TRIAL; HER-2/NEU-DERIVED PEPTIDES; BOOSTER INOCULATIONS; DENDRITIC CELLS; HLA-A2; PEPTIDE; CTL EPITOPES; CANCER; BREAST;

D O I：

10.2217/fon-2015-0054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial. This article covers the preclinical and clinical development of nelipepimut-S.

引用

页码：1321 / 1329

页数：9

共 34 条

[1]

Anderson BW, 2000, CLIN CANCER RES, V6, P4192

[2] Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells [J].

Brossart, P ;

Wirths, S ;

Stuhler, G ;

Reichardt, VL ;

Kanz, L ;

Brugger, W .

BLOOD, 2000, 96 (09) :3102-3108

[3]

Brossart P, 1998, CANCER RES, V58, P732

[4] A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer [J].

Chianese-Bullock, Kimberly A. ;

Irvin, William P., Jr. ;

Petroni, Gina R. ;

Murphy, Cheryl ;

Smolkin, Mark ;

Olson, Walter C. ;

Coleman, E'lizabeth ;

Boerner, Scott A. ;

Nail, Carmel J. ;

Neese, Patrice Y. ;

Yuan, Arlene ;

Hogan, Kevin T. ;

Slingluff, Craig L., Jr. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (04) :420-430

[5] Overcoming Cancer Immune Tolerance and Escape [J].

Clifton, Guy T. ;

Peoples, George E. .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :749-751

[6] Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion [J].

Czerniecki, Brian J. ;

Koski, Gary K. ;

Koldovsky, Ursula ;

Xu, Shuwen ;

Cohen, Peter A. ;

Mick, Rosemarie ;

Nisenbaum, Harvey ;

Pasha, Terry ;

Xu, Min ;

Fox, Kevin R. ;

Weinstein, Susan ;

Orel, Susan G. ;

Vonderheide, Robert ;

Coukos, George ;

DeMichele, Angela ;

Araujo, Louis ;

Spitz, Francis R. ;

Rosen, Mark ;

Levine, Bruce L. ;

June, Carl ;

Zhang, Paul J. .

CANCER RESEARCH, 2007, 67 (04) :1842-1852

[7] Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer [J].

Disis, Mary L. ;

Wallace, Danelle R. ;

Gooley, Theodore A. ;

Dang, Yushe ;

Slota, Meredith ;

Lu, Hailing ;

Coveler, Andrew L. ;

Childs, Jennifer S. ;

Higgins, Doreen M. ;

Fintak, Patricia A. ;

dela Rosa, Corazon ;

Tietje, Kathleen ;

Link, John ;

Waisman, James ;

Salazar, Lupe G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4685-4692

[8] Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines [J].

Disis, ML ;

Gooley, TA ;

Rinn, K ;

Davis, D ;

Piepkorn, M ;

Cheever, MA ;

Knutson, KL ;

Schiffman, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2624-2632

[9]

Fisk B, 1997, CANCER RES, V57, P87

[10] Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: Implications for optimization of antigen presentation and tumor-specific CTL induction [J].

Fisk, B ;

Savary, C ;

Hudson, JM ;

OBrian, CA ;

Murray, JL ;

Wharton, JT ;

Ioannides, CG .

JOURNAL OF IMMUNOTHERAPY, 1995, 18 (04) :197-209

← 1 2 3 4 →